The clinical utility of microsatellite instability in colorectal cancer

[Display omitted] Microsatellite instability (MSI) became the spotlight after the US FDA’ s approval of MSI as an indication of immunotherapy for cancer patients. Immunohistochemical detection of loss of MMR proteins and PCR amplification of specific microsatellite repeats are widely used in clinica...

Full description

Saved in:
Bibliographic Details
Published inCritical Reviews in Oncology/Hematology Vol. 157; p. 103171
Main Authors Diao, Zhenli, Han, Yanxi, Chen, Yuqing, Zhang, Rui, Li, Jinming
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.01.2021
Elsevier BV
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] Microsatellite instability (MSI) became the spotlight after the US FDA’ s approval of MSI as an indication of immunotherapy for cancer patients. Immunohistochemical detection of loss of MMR proteins and PCR amplification of specific microsatellite repeats are widely used in clinical practice. Next-generation sequencing is a promising tool for identifying MSI patients. Circulating tumour DNA provides a convenient alternative when tumour tissue is unavailable. MSI detection is an effective tool to screen for Lynch syndrome. Early-stage CRC patients with MSI generally have a better prognosis and a reduced response to chemotherapy; instead, they are more likely to respond to immunotherapy. In this review, we aimed to assess the clinical utility of MSI as a biomarker in CRC. We will provide an overview of the available methods for evaluation of the analytical validity of MSI detection and elaborate the evidence on the clinical validity of MSI in the management of CRC patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1040-8428
1879-0461
1879-0461
DOI:10.1016/j.critrevonc.2020.103171